Fupentixol Dihydrochloride

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

氟哌噻吨用于治疗精神分裂症以及抗焦虑症和抑郁症。

Flupentixol is used in therapy of schizophrenia as well as in anxiolytic and depressive disorders.(In Vitro):Flupentixol (2.5-40 μM; 72 h) treatment inhibits the viability of lung cancer cells in a dose-dependent manner.Flupentixol (2.5-40 μM; 24 h) induces apoptosis in lung cancer cells.Flupentixol (2.5-15 μM; 24 h) inhibits p-AKT and Bcl-2 expression levels.(In Vivo):Flupentixol (intragastric injection; 40 mg/kg; once daily; 21 d) suppresses A549 xenografted tumor growth in nude mice.

Flupentixol (2.5-40 μM; 72 h) treatment inhibits the viability of lung cancer cells in a dose-dependent manner.Flupentixol (2.5-40 μM; 24 h) induces apoptosis in lung cancer cells.Flupentixol (2.5-15 μM; 24 h) inhibits p-AKT and Bcl-2 expression levels. Cell Viability AssayCell Line:A549, H661, SK-SEM-1, and NCAL-H520 cells Concentration:2.5, 5, 10, 20, or 40 μM Incubation Time:72 hours Result:Showed the IC50s of 5.708 μM and 6.374 μM for A549 and H661 cells, respectively.Apoptosis Analysis Cell Line:A549 and H661 cells Concentration:5, 10, 20 and 40 μM Incubation Time:24 hours Result:Increased the percentage of cells in early apoptosis compared with the negative control in both A549 and H661 (p<0.05).Induced the cleavage of PARP and caspase-3 in a dose-dependent manner.Western Blot Analysis Cell Line:A549 and H661 cells Concentration:2.5, 5, 10, and 15 μM Incubation Time:24 hours Result:Decreased AKT phosphorylation levels in a dose-dependent manner, decreased the expression levels of Bcl-2.

Flupentixol (intragastric injection; 40 mg/kg; once daily; 21 d) suppresses A549 xenografted tumor growth in nude mice. Animal Model:BALB/C nude mice injected with A549 cellsDosage:40 mg/kg Administration: Intragastric injection; 40 mg/kg; once daily; 21 days Result:Reduced tumor volumes compared to the vehicle control (p<0.05), reduced tumor weights by 64.1% (p<0.05).

Flupenthixol dihydrochloride | Flupentixol dihydrochloride | (E/Z)-Flupentixol Dihydrochloride

GPCR/G Protein

Dopamine Receptor

D1 D2

Neurological Disease

schizophrenia

2413-38-9

507.43

C23H27Cl2F3N2OS

>98% (HPLC)

DMSO: 95 mg/mL;Water: 95 mg/mL;Ethanol: 25 mg/mL

Cl.Cl.OCCN1CCN(CC\C=C2\c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1

——

(-20℃)

With Ice Pack

≥ 2 years